April 24 (Bloomberg) — Johnson & Johnson won U.S. approval of a rheumatoid arthritis drug designed to be injected less often than its top-selling product, Remicade, for the crippling disease.
Arthritis Information
Arthritis Information
April 24 (Bloomberg) — Johnson & Johnson won U.S. approval of a rheumatoid arthritis drug designed to be injected less often than its top-selling product, Remicade, for the crippling disease.
